To Cycle or Fight-CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity

Area of Science:

• Oncology
• Immunology
• Cell Biology

Background:

• Aberrant cell proliferation due to cell division dysregulation is a hallmark of cancer, making cell-cycle control a key therapeutic target.
• Selective cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are approved for hormone receptor-positive/HER2-negative advanced breast cancer.
• Emerging evidence suggests CDK4/6 inhibitors possess immunomodulatory effects beyond cytostasis.

Purpose of the Study:

• To review the role of CDK4/6 inhibitors in cell-cycle regulation and their impact on immune cells, particularly T cells.
• To synthesize preclinical evidence demonstrating the augmentation of anticancer immunity by CDK4/6 inhibitors.
• To provide a framework for understanding cell-cycle control's role in anticancer immunity and discuss future therapeutic strategies.

Main Methods:

• Literature review of preclinical studies and clinical trials.
• Analysis of the biological effects of CDK4/6 inhibitors on T cell and immune cell proliferation.
• Synthesis of data on the interplay between cell-cycle control and anti-tumor immune responses.

Main Results:

• CDK4/6 inhibitors are not only cytostatic but also play critical roles in tumor-immune cell interactions.
• These inhibitors can enhance lymphocyte proliferation, a necessary step for effective immune responses.
• Preclinical data support the concept that CDK4/6 inhibition can augment anticancer immunity.

Conclusions:

• CDK4/6 inhibitors hold potential beyond direct tumor cell killing by modulating the immune microenvironment.
• Understanding the cell cycle's role in anticancer immunity is crucial for developing novel immunotherapies.
• Further clinical trials are investigating rational combinations of CDK4/6 inhibitors with immunotherapy.